Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 24, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $380.00 to $19,195,500.00.

Highlighted Stocks Traded by Insiders:

Ascent Capital Group (ASCMA) - FREE Research Report

Fitzgerald William R, who is Chairman, President & CEO at Ascent Capital Group, bought 1,000 shares at $39.00 on March 24, 2015. Following this transaction, the Chairman, President & CEO owned 139,637 shares meaning that the stake was boosted by 0.72% with the 1,000-share transaction.

The shares most recently traded at $41.46, up $2.46, or 5.93% since the insider transaction. Historical insider transactions for Ascent Capital Group go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 1,107
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 1,107
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 1,107

The average volume for Ascent Capital Group has been 88,300 shares per day over the past 30 days. Ascent Capital Group has a market cap of $555.7 million and is part of the services sector and diversified services industry. Shares are down 20.01% year-to-date as of the close of trading on Tuesday.

Ascent Capital Group, Inc., through its subsidiary, Monitronics International, Inc., provides security alarm monitoring and related services to residential and business subscribers in the United States and Canada. Currently, there is 1 analyst who rates Ascent Capital Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ASCMA - FREE

TheStreet Quant Ratings

rates Ascent Capital Group as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally high debt management risk. Get the full

Ascent Capital Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Citizens and Northern (CZNC) - FREE Research Report

Scovill J Bradley, who is President & CEO at Citizens and Northern, bought 1,400 shares at $20.10 on March 24, 2015. Following this transaction, the President & CEO owned 6,574 shares meaning that the stake was boosted by 27.06% with the 1,400-share transaction.

The shares most recently traded at $20.27, up $0.17, or 0.84% since the insider transaction. Historical insider transactions for Citizens and Northern go as follows:

  • 4-Week # shares bought: 47
  • 4-Week # shares sold: 650
  • 12-Week # shares bought: 585
  • 12-Week # shares sold: 650
  • 24-Week # shares bought: 777
  • 24-Week # shares sold: 2,150

The average volume for Citizens and Northern has been 23,600 shares per day over the past 30 days. Citizens and Northern has a market cap of $246.1 million and is part of the financial sector and banking industry. Shares are down 2.95% year-to-date as of the close of trading on Tuesday.

Citizens & Northern Corporation operates as the bank holding company for Citizens & Northern Bank that provides a range of banking and mortgage services to individual and corporate customers in North Central Pennsylvania and Southern New York. The stock currently has a dividend yield of 5.18%. The company has a P/E ratio of 14.5. Currently, there are no analysts who rate Citizens and Northern a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CZNC - FREE

TheStreet Quant Ratings

rates Citizens and Northern as a

buy

. The company's strengths can be seen in multiple areas, such as its expanding profit margins, good cash flow from operations, increase in net income, growth in earnings per share and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Citizens and Northern Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Medidata Solutions (MDSO) - FREE Research Report

De Vries Glen Michael, who is President at Medidata Solutions, sold 20,000 shares at $49.89 on March 24, 2015. Following this transaction, the President owned 898,441 shares meaning that the stake was reduced by 2.18% with the 20,000-share transaction.

Sherif Tarek, who is Chairman & CEO at Medidata Solutions, sold 20,000 shares at $49.89 on March 24, 2015. Following this transaction, the Chairman & CEO owned 749,231 shares meaning that the stake was reduced by 2.6% with the 20,000-share transaction.

The shares most recently traded at $49.80, down $0.09, or 0.18% since the insider transaction. Historical insider transactions for Medidata Solutions go as follows:

  • 4-Week # shares bought: 2,400
  • 4-Week # shares sold: 6,890
  • 12-Week # shares bought: 2,400
  • 12-Week # shares sold: 11,945
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 65,280

The average volume for Medidata Solutions has been 391,300 shares per day over the past 30 days. Medidata Solutions has a market cap of $2.8 billion and is part of the technology sector and computer software & services industry. Shares are up 5.32% year-to-date as of the close of trading on Tuesday.

Medidata Solutions, Inc. provides cloud-based clinical development solutions for life sciences in the United States and internationally. The company offers applications and data analytics for clinical development. The company has a P/E ratio of 455.3. Currently, there are 8 analysts who rate Medidata Solutions a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDSO - FREE

TheStreet Quant Ratings

rates Medidata Solutions as a

hold

. The company's strengths can be seen in multiple areas, such as its increase in net income, robust revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and premium valuation. Get the full

Medidata Solutions Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null